Specify a stock or a cryptocurrency in the search bar to get a summary
Human Metabolome Technologies Inc
6090Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan. Address: 246-2 Mizukami Kakuganji, Tsuruoka, Japan, 997-0052
Analytics
WallStreet Target Price
–P/E ratio
13.7369Dividend Yield
2.37 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 6090
Dividend Analytics 6090
Dividend growth over 5 years
–Continuous growth
1 yearPayout Ratio 5 years average
21 %Dividend History 6090
Stock Valuation 6090
Financials 6090
Results | 2019 | Dynamics |